Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom

Tremlett, H. L.; Luscombe, D. K.; Wiles, C. M.
September 1998
Journal of Neurology, Neurosurgery & Psychiatry;Sep1998, p362
Academic Journal
No abstract available.


Related Articles

  • A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Annovazzi, Pietro; Tomassini, Valentina; Bodini, Benedetta; Boffa, Laura; Calabrese, Massimiliano; Cocco, Eleonora; Cordioli, Cinzia; Luca, Giovanna; Frisullo, Giovanni; Gallo, Antonio; Malucchi, Simona; Paolicelli, Damiano; Pesci, Ilaria; Radaelli, Marta; Ragonese, Paolo; Roccatagliata, Luca; Tortorella, Carla; Vercellino, Marco; Zipoli, Valentina; Gasperini, Claudio // Neurological Sciences;Feb2013, Vol. 34 Issue 2, p197 

    Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists...

  • NEED TO KNOW MS. Young, Carolyn // Pulse;5/4/2006, Vol. 66 Issue 18, p44 

    This article presents an interview with Carolyn Young, a consultant neurologist at the Walton Centre for Neurology and Neurosurgery in Great Britain. When asked about the different kind of multiple sclerosis, she stated that there are many ways of categorizing the complex disease. She suggests...

  • Multiple sclerosis.  // Mayo Clinic Health Letter;Jan2003, Vol. 21 Issue 1, p6 

    Focuses on the treatment for multiple sclerosis in the U.S. Use of beta interferons; Efficacy of chemotherapy; Capability of intravenous corticosteroid treatment.

  • Estimating the Prevalence of Multiple Sclerosis in the United Kingdom by Using Capture-Recapture Methodology. Forbes, Raeburn B.; Swingler, Robert J. // American Journal of Epidemiology;1999, Vol. 149 Issue 11, p1016 

    The geographic distribution of multiple sclerosis is nonrandom, as the disease is more prevalent in temperate than in tropical regions. Surveys conducted between 1970 and 1996 suggest that multiple sclerosis is more prevalent in the northern part of the United Kingdom than in the southern part....

  • Service framework threatened by shortage of neurologists. White, Caroline // BMJ: British Medical Journal (International Edition);3/19/2005, Vol. 330 Issue 7492, p615 

    Reports on the threat to the U.K. government's national service framework on long term conditions posed by the shortage of neurologists and the absence of dedicated funding. Number of people in the United Kingdom affected by neurological disorders, including epilepsy, multiple sclerosis and...

  • Advances in the treatment of multiple sclerosis. Smiroldo, Joanna; Coyle, P.K. // Patient Care;6/15/1999, Vol. 33 Issue 11, p88 

    Focuses on multiple sclerosis (MS) and treatment options. Major acquired neurologic disease in young adults in the United States; Epidemiology; Genetic susceptibility triggered by environmental factors; Pathologic process; Use of magnetic resonance imaging (MRI) for diagnosis; Prognostic...

  • Removal of alemtuzumab for patients with aggressive MS. Thompson, Alan J.; Giovannoni, Gavin // BMJ: British Medical Journal;1/26/2013, Vol. 346 Issue 7892, p10 

    The author highlights on the need for improving treatment of agressive multiple sclerosis, and mentions on the withdrawal of Alemtuzumab a product of Genzym, which was used to treat active relapsing-remitting multiple sclerosis, with effect from August 8th, 2012 in the United Kingdom, although...

  • To Treat or Not to Treat With Alemtuzumab? McKnight, Whitney // Neurology Reviews;Jul2014, Vol. 22 Issue 7, p22 

    The article focuses on whether to treat or not to treat multiple sclerosis with Alemtuzumab. Many neurologists have raised concerns about alemtuzumab's safety. Alemtuzumab can be used as an effective induction therapy up-front and for a limited amount of time. Some neurologists believe that the...

  • Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy. Coyle, Patricia K.; Foley, John F.; Fox, Edward J.; Jeffery, Douglas R.; Munschauer III, Frederick E.; Tornatore, Carlo // Multiple Sclerosis (13524585);Nov2009 Supplement, Vol. 15 Issue S4, pS26 

    Natalizumab, a humanized monoclonal antibody directed against a4-integrin is a first-in-class disease-modifying therapy for the treatment of relapsing multiple sclerosis. Natalizumab is highly effective but has been associated with a risk of progressive multifocal leukoencephalopathy. Since the...

  • Identifying barriers to using an MS drug.  // Momentum (19403410);Summer2009, Vol. 2 Issue 3, p37 

    The article focuses on the results of a study on the identification of barriers to using drugs for multiple sclerosis (MS) conducted by Sarah Minden, published in the June 2008 issue of "Multiple Sclerosis." Based on the results, patients who never use disease-modifying therapies (DMTs) had the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics